Overview
Janashakthi Life is a Sri Lankan life and health insurer focused on individual and group protection, supported by an investment portfolio and asset‑liability management. The key change in the latest quarter is profit compression despite revenue growth, while the share base was split 1:3 in April to improve trading liquidity.
Price performance
The share fell 14.8% over three months against the ASPI’s -6.5%, but is up 78.9% over 12 months versus the index’s 9.3%. Over six months it slipped 3.5% versus the ASPI’s -11.3%. A 1:3 share split on 9 Apr 2026 means as‑traded returns diverge from restated history (for example, the as‑traded 6‑month change shows -68.0%), reflecting the split rather than a different underlying performance. The 52‑week range is LKR 23.83 to LKR 54.90.
Valuation
JINS screens inexpensive: P/E 8.91 sits near the sector’s cheap end (11th percentile) and P/B 0.575 is the sector’s lowest (0th percentile). That discount is hard to reconcile with a 20.8% ROE. The dividend yield is 7.8% versus a 7.1% sector median, with dividend cover of 1.43x (payout 69.9%).
News and sentiment
Coverage has been unusually quiet in the last 30 days (zero articles vs a 1.7 per month baseline). Over the last 90 days, material coverage was positive (2 of 2 articles). Company releases in May reported Q1 2026 GWP of LKR 2.6bn, up 42% year‑on‑year, with new business up 25%. Two independent non‑executive directors were appointed on 20 Apr 2026. A 1:3 share split went ex on 9 Apr 2026. The most recent cash dividends were interim payments with ex‑dates 2 Jul 2025 and 24 Dec 2025.
Financials
For the quarter to 31 Mar 2026, revenue rose 22.6% year‑on‑year to LKR 3.29 billion, but operating profit fell 27.4% to LKR 0.24 billion and net profit fell 61.1% to LKR 0.11 billion. Gross margin was 23.9% (among its worst March quarters, 3 of 4). Operating margin was 7.2%, down 5.0 points year‑on‑year; within March quarters this is 2 of 4 but middling across all quarters. Net margin was 3.5%, among its worst (11 of 12 all‑quarters; 5 of 6 March), reflecting a below‑the‑line drag of LKR 0.12 billion (finance costs, tax, associates and FX). Total equity stood at LKR 16.75 billion. The share subdivision on 9 Apr 2026 occurred after this quarter, so subsequent per‑share figures step down mechanically. On a full‑year view to 31 Dec 2025, ROE was 20.8% and the reported net margin was 25.2%; high net margins are common in insurers where investment income, not revenue, is the primary driver.
Risks
Earnings sensitivity is elevated: the latest quarter’s net profit fell 61.1% year‑on‑year and net margin printed near the bottom of its history. Dividend flexibility is limited if profits remain soft, with a 69.9% payout and 1.43x cover. The share carries high market sensitivity (beta to ASPI 2.1). Information flow has been quiet in the last month, which can add to price volatility. Sector conditions remain rate‑ and currency‑sensitive; as at 6 Aug 2026, bond yields were broadly steady around 11% and the rupee near 335.8 per US dollar, shaping reinvestment returns and reinsurance cost translation.
Outlook
As at 6 Aug 2026, the next numbers are the 2026‑06‑30 quarter, due now and expected by 28 Oct 2026. The key watch is whether the strong Q1 GWP growth reported in May translates into an earnings rebound and a lighter below‑the‑line burden. A clean recovery would support the current valuation gap; another weak print would keep the discount in place.